Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil
Crossref DOI link: https://doi.org/10.1007/s12264-023-01138-2
Published Online: 2023-10-28
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wu, Peng-Peng
Cao, Bi-Rong
Tian, Fu-Yun
Gao, Zhao-Bing
Text and Data Mining valid from 2023-10-28
Version of Record valid from 2023-10-28
Article History
Received: 27 March 2023
Accepted: 16 August 2023
First Online: 28 October 2023
Conflict of interest
: The authors declare no competing interests.